OS Therapies Reports Increased Net Loss and Operating Expenses in Latest 10-Q Filing

OS Therapies Incorporated has reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2025. The company recorded a net loss of approximately $3.9 million, a substantial increase from the $1.5 million loss reported in the same period last year. This increase in losses is attributed to a rise in operating expenses, which totaled $5 million, compared to $0.9 million in the prior year. The primary drivers of these expenses were research and development costs, which surged to $1.3 million from $0.4 million, and general and administrative expenses, which rose to $3.7 million from $0.3 million.

In terms of liquidity, OS Therapies reported cash and cash equivalents of $3 million as of March 31, 2025, down from $5.5 million at the end of the previous fiscal year. The company has funded its operations primarily through the issuance of convertible notes and Series A securities, raising a total of approximately $34.6 million to date. The company anticipates that its existing cash, along with net proceeds from recent financing activities, will support its operations for the next nine to twelve months.

Strategically, OS Therapies has made notable advancements, including the completion of a Securities Purchase Agreement on December 24, 2024, which resulted in the issuance of 1.8 million shares of Series A Preferred Stock and warrants, generating gross proceeds of approximately $7.1 million. Additionally, the company announced the acquisition of HER2-related assets from Ayala Pharmaceuticals, which includes two investigational new drug filings with the FDA. This acquisition is expected to enhance the company's product pipeline and market position.

Operationally, OS Therapies is focused on its lead product candidate, OST-HER2, which is currently in a Phase IIb clinical trial for Osteosarcoma. The trial achieved its primary endpoint with statistical significance, and the company plans to request a meeting with the FDA to discuss the data and potential pathways for regulatory approval. The company is also exploring the use of OST-HER2 in other solid tumors, indicating a strategic expansion of its product applications.

Looking ahead, OS Therapies remains committed to advancing its clinical programs and securing additional funding to support its growth. The company acknowledges the challenges of operating at a loss and the need for continued capital to sustain its operations and development efforts. As it navigates these challenges, OS Therapies aims to leverage its recent strategic developments to enhance its market presence and drive future growth.